Alzheimer Disease, Dementia, Mild, Dementia Moderate
Conditions
Keywords
Xanamem, Actinogen, Alzheimer's Disease, Cortisol, emestedastat
Brief summary
Xanamem® is being developed as a potential treatment for symptomatic, early stages of Alzheimer's Disease (AD) and Major Depressive Disorder (MDD). This XanaMIA Phase 2b/3 study is to investigate the safety, tolerability, and efficacy of Xanamem in in mild or moderate dementia due to AD. Trial participants will be randomized to either receive 10mg of Xanamem once daily or a placebo for 36 weeks at a 1:1 ratio in a double-blinded fashion. Participants who have completed the main trial will be eligible to participate in an open-label phase, which involves treatment with 10mg Xanamem once daily for a treatment period of up to a maximum of 108 weeks. The OLE is intended to finish when all participants have completed at least 60 weeks of treatment and a follow-up visit 4 weeks later.
Interventions
DRUGXanamem
Xanamem drug product is formulated as an immediate-release film-coated tablet formulation for oral administration. Each Xanamem tablet contains 10 mg Xanamem (UE2343) drug substance and excipients.
DRUGPlacebo
Matching placebo which is identical in appearance to the test product (10 mg Xanamem once daily) except that it contains no active ingredient.
Sponsors
Actinogen Medical
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Intervention model description
After completion of the randomized, placebo-controlled, parallel-group main trial, participants who have completed the main trial will be eligible to take part in an open-label phase with 10 mg Xanamem
Eligibility
Sex/Gender
ALL
Age
50 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Male or female aged 50 years or older, inclusive at the time of Screening. * Clinical syndrome of mild or moderate dementia, likely to be due to AD in the opinion of the Investigator, at Screening, including meeting the following criteria: 1. Clinical Dementia Rating (CDR) global score of 0.5 to 1.0 2. Mini-mental state examination (MMSE) score of 18 to 26 3. Magnetic resonance imaging (MRI) or computerized tomography (CT) scan within 1 year prior to randomization that excludes alternative diagnoses for dementia such as large stroke, likely vascular dementia, brain tumor, subdural hematoma, or other non-AD dementia type findings 4. Positive plasma AD biomarker signature at Pre-screening, comprising fasting levels of a tau species protein. * If receiving symptomatic AD medications, the dosing regimen must have been stable for 3 months prior to Screening. * Has a consenting trial partner who, in the Investigator's judgment, has frequent and sufficient contact with the participant to be able to provide accurate information as to the participant's cognitive and functional abilities. The trial partner must be available to provide information to the Investigator and trial site staff about the participant and agrees to attend all trial site visits in person for scale completion. A trial partner should be available for the duration of the trial. The measure of adequate availability will be at the Investigator's discretion. * Participants must be able to comfortably abstain from caffeine intake for 4 hours prior to scheduled cognitive assessments. * Smokers are eligible if they are able to comfortably abstain from nicotine / tobacco products for 2 hours prior to scheduled cognitive assessments. * Must provide written informed consent to participate in the trial and be willing and able to participate for the maximum of 9 months of treatment and up to 11.5 months of site visits.
Exclusion criteria
* Use of anti-amyloid or anti-tau antibody within 6 months. * Diagnosis of a non-AD dementia including traumatic brain injury. * Diagnosis of an active major mental illness of concern in the opinion in the Investigator, including major depressive disorder, bipolar illness, or schizophrenia. * Participation in another clinical trial of a drug or device * Has a body mass index or body weight that will interfere with participation in the trial, including inadequate venous access to complete the trial assessments, to be determined at the discretion of the Investigator. * Previous clinically significant systemic illness or infection, including test positive COVID-19, within the past 4 weeks prior to Screening. * Clinical diagnosis of Type I or Type II diabetes requiring insulin. * Exhibit physical, cognitive, or language impairments, in the opinion of the Investigator, of such severity as to adversely affect the validity of the data derived from the neuropsychological tests. * Trial participants with evidence of current infection with HIV, hepatitis B, or hepatitis C. * Participants with a history of clinically significant drug abuse or addiction in the past 2 years * Evidence or history of alcohol abuse
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Effects of 10 mg Xanamem on integrated cognitive and functional abilities | 36 weeks | Change from Baseline to end of treatment (EOT) in the Clinical Dementia Ratio - Sum of Boxes (CDR-SB). The CDR-SB is calculated as an average score, with lower scores indicating improvement. |
| Incidence and severity of treatment-emergent adverse events (TEAEs) [safety and tolerability of Xanamem] | 36 weeks | Incidence and severity of TEAEs |
Countries
Australia, United States
Contacts
STUDY_DIRECTORGlobal Program Lead
Actinogen Medical Ltd
Outcome results
None listed